Market capitalization | $3.11b |
Enterprise Value | $2.85b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 50.55 |
EV/Sales (TTM) EV/Sales | 6.71 |
P/S ratio (TTM) P/S ratio | 7.31 |
P/B ratio (TTM) P/B ratio | 2.64 |
Revenue growth (TTM) Revenue growth | 23.95% |
Revenue (TTM) Revenue | $425.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a Veracyte Inc forecast:
12 Analysts have issued a Veracyte Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 425 425 |
24%
24%
|
|
Gross Profit | 276 276 |
33%
33%
|
|
EBITDA | 35 35 |
102%
102%
|
EBIT (Operating Income) EBIT | 11 11 |
187%
187%
|
Net Profit | -9.27 -9.27 |
81%
81%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Marc Stapley |
Employees | 815 |
Founded | 2006 |
Website | www.veracyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.